Tag:
TNFerade
Latest Headlines
Latest Headlines
GenVec shares implode on pancreatic cancer trial failure
GenVec is reeling after its lead therapy TNFerade flunked a Phase III trial for pancreatic cancer. An interim analysis found that the gene therapy was unlikely to prove effective, causing the
GenVec shares soar on orphan cancer drug designation
Regulators at the FDA have presented GenVec with orphan drug status for TNFerade, an experimental therapy that spurs development of an immune system protein which helps fight advanced pancreatic
